Anti Tumo CAS 127-07-1 Hydroxyurea Powder Hydroxyurea

• Customization: Available
• CAS No.: 127-07-1
• Formula: CH4n2o2
• Model NO.: QS-Hydroxyurea
• EINECS: 204-821-7
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: >12 Months
• Nutrient Composition: Hydroxyurea
• Resource: Hydroxyurea
• The content of active substances: >99%
• Product Name: Hydroxyurea
• Name: Hydroxyurea Powder
• Appearance: White Powder
• Colour: White
• Grade: Veterinary Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Density: 1.457
• Mf: CH4n2o2
• MW: 76.05466
• Melting Point: 142c
• Boiling Point: 136.04c
• Flash Point: 88.1c
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Hydroxyurea
• Origin: Xi`an
• Production Capacity: 1000kg/Month

Product Description

Anti Tumor Hydroxyurea CAS 127-07-1 Hydroxyurea

 

Product Description

Product Details

Product Name	Hydroxyurea
Appearance	Hydroxyurea Powder
Assay	>99%
MW	76.05466
MF	CH4N2O2
Melting point	142C
Density	1.457

Hydroxyurea appears as white needle-like crystals with a melting point of 70-72°C (decomposition) or 141°C upon decomposition. It is soluble in water and hot ethanol, slightly soluble in cold ethanol, and insoluble in ethyl ether and benzene. This compound is unstable when exposed to water or heat and is odorless and tasteless. As an anticancer medication, hydroxyurea is primarily used to treat chronic myelogenous leukemia. It exerts its therapeutic effects by inducing the production of a molecule within bacteria that is toxic to them, leading to their destruction.

Application&Function

Hydroxyurea is an antimetabolite anticancer drug that primarily targets proliferating cells during the G1 and S phases of the cell cycle, delaying the G1/S interface. It is a cell cycle-specific agent with significant antitumor properties. The drug works by inactivating ribonucleotide reductase through the formation of free nitric oxide, which binds to tyrosine residues at the enzyme's active site. This inhibition prevents the synthesis of deoxynucleotides, essential for DNA replication and repair, thereby halting the growth of cancer cells.

Hydroxyurea is clinically used in the treatment of chronic myelogenous leukemia, metastatic ovarian cancer, primary squamous cell carcinoma of the head and neck, and refractory psoriasis. As an antitumor drug, it plays a crucial role in managing these conditions by selectively targeting rapidly dividing cells and disrupting their proliferation. Its mechanism of action and therapeutic applications make it a valuable option in oncology and dermatology.

Specification